81 related articles for article (PubMed ID: 25859977)
1. Case Study: discovery of inhibitors of the MDM2-p53 protein-protein interaction.
Liu L; Bernard D; Wang S
Methods Mol Biol; 2015; 1278():567-85. PubMed ID: 25859977
[TBL] [Abstract][Full Text] [Related]
2. Rapid screening of protein-protein interaction inhibitors using the protease exclusion assay.
Nirantar SR; Li X; Siau JW; Ghadessy FJ
Biosens Bioelectron; 2014 Jun; 56():250-7. PubMed ID: 24508816
[TBL] [Abstract][Full Text] [Related]
3. Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.
Gessier F; Kallen J; Jacoby E; Chène P; Stachyra-Valat T; Ruetz S; Jeay S; Holzer P; Masuya K; Furet P
Bioorg Med Chem Lett; 2015 Sep; 25(17):3621-5. PubMed ID: 26141769
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule MDM2-p53 inhibitors: recent advances.
Zhang B; Golding BT; Hardcastle IR
Future Med Chem; 2015; 7(5):631-45. PubMed ID: 25921402
[TBL] [Abstract][Full Text] [Related]
5. A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction.
Surmiak E; Twarda-Clapa A; Zak KM; Musielak B; Tomala MD; Kubica K; Grudnik P; Madej M; Jablonski M; Potempa J; Kalinowska-Tluscik J; Dömling A; Dubin G; Holak TA
ACS Chem Biol; 2016 Dec; 11(12):3310-3318. PubMed ID: 27709883
[TBL] [Abstract][Full Text] [Related]
6. Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity.
Brandão P; Loureiro JB; Carvalho S; Hamadou MH; Cravo S; Moreira J; Pereira D; Palmeira A; Pinto M; Saraiva L; Cidade H
Eur J Med Chem; 2018 Aug; 156():711-721. PubMed ID: 30041135
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
Zhao Y; Aguilar A; Bernard D; Wang S
J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
[TBL] [Abstract][Full Text] [Related]
8. A fluorescent probe for imaging p53-MDM2 protein-protein interaction.
Liu Z; Miao Z; Li J; Fang K; Zhuang C; Du L; Sheng C; Li M
Chem Biol Drug Des; 2015 Apr; 85(4):411-7. PubMed ID: 25226874
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule inhibitors of MDM2 as new anticancer therapeutics.
Dickens MP; Fitzgerald R; Fischer PM
Semin Cancer Biol; 2010 Feb; 20(1):10-8. PubMed ID: 19897042
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships.
Miyazaki M; Kawato H; Naito H; Ikeda M; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Aonuma M; Soga T
Bioorg Med Chem Lett; 2012 Oct; 22(20):6338-42. PubMed ID: 22995624
[TBL] [Abstract][Full Text] [Related]
11. Identification of small-molecule inhibitors of the human S100B-p53 interaction and evaluation of their activity in human melanoma cells.
Yoshimura C; Miyafusa T; Tsumoto K
Bioorg Med Chem; 2013 Mar; 21(5):1109-15. PubMed ID: 23375094
[TBL] [Abstract][Full Text] [Related]
12. P53 mdm2 inhibitors.
Khoury K; Dömling A
Curr Pharm Des; 2012; 18(30):4668-78. PubMed ID: 22650254
[TBL] [Abstract][Full Text] [Related]
13. Proximity-enabled bioreactivity to generate covalent peptide inhibitors of p53-Mdm4.
Hoppmann C; Wang L
Chem Commun (Camb); 2016 Apr; 52(29):5140-3. PubMed ID: 26996321
[TBL] [Abstract][Full Text] [Related]
14. Competition NMR for Detection of Hit/Lead Inhibitors of Protein-Protein Interactions.
Musielak B; Janczyk W; Rodriguez I; Plewka J; Sala D; Magiera-Mularz K; Holak T
Molecules; 2020 Jul; 25(13):. PubMed ID: 32630327
[TBL] [Abstract][Full Text] [Related]
15. Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction.
Beloglazkina A; Zyk N; Majouga A; Beloglazkina E
Molecules; 2020 Mar; 25(5):. PubMed ID: 32156064
[TBL] [Abstract][Full Text] [Related]
16. High content screening biosensor assay to identify disruptors of p53-hDM2 protein-protein interactions.
Hua Y; Strock CJ; Johnston PA
Methods Mol Biol; 2015; 1278():555-65. PubMed ID: 25859976
[TBL] [Abstract][Full Text] [Related]
17. Synthetic Proteins Potently and Selectively Bind the Oncoprotein Gankyrin, Modulate Its Interaction with S6 ATPase, and Suppress Gankyrin/MDM2-Dependent Ubiquitination of p53.
Chapman AM; McNaughton BR
ACS Chem Biol; 2015 Aug; 10(8):1880-6. PubMed ID: 25955581
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci.
Frosi Y; Inoue K; Ramlan SR; Lane DP; Watanabe T; Brown CJ
Sci Rep; 2019 Nov; 9(1):17933. PubMed ID: 31784573
[TBL] [Abstract][Full Text] [Related]
19. Phase-separated condensate-aided enrichment of biomolecular interactions for high-throughput drug screening in test tubes.
Zhou M; Li W; Li J; Xie L; Wu R; Wang L; Fu S; Su W; Hu J; Wang J; Li P
J Biol Chem; 2020 Aug; 295(33):11420-11434. PubMed ID: 32461254
[TBL] [Abstract][Full Text] [Related]
20. AlphaSpace: Fragment-Centric Topographical Mapping To Target Protein-Protein Interaction Interfaces.
Rooklin D; Wang C; Katigbak J; Arora PS; Zhang Y
J Chem Inf Model; 2015 Aug; 55(8):1585-99. PubMed ID: 26225450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
